Balchem: 3 Key Takeaways for Long-Term Investors

Balchem reported record Q3 2026 sales of $291 million with 8.6% year-over-year growth. The company is expanding its science-backed specialty ingredients like VitaCholine and K2VITAL DELTA from infant nutrition into adult cognitive and cardiovascular markets. Proprietary encapsulation technology is driving adoption in animal nutrition, while a high-margin product mix is fueling segment profitability. The company achieved its 29th consecutive quarter of year-over-year adjusted EBITDA growth.